Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
VALNEVAMarch 8, 2021 GMT
The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program
VLA15 will be tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg
VLA15 is the only Lyme disease vaccine candidate in active clinical development
Saint-Herblain (France) and New York, NY, March 8, 2021 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. (NYSE: PFE) today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress int
Press release content from Business Wire. The AP news staff was not involved in its creation.
Middle East and Africa Aircraft Floor Panel Market Forecast to 2027 - Mounting Emphasis on Use of Lightweight Materials - ResearchAndMarkets.com
March 8, 2021 GMT
DUBLIN (BUSINESS WIRE) Mar 8, 2021
Wide Body Aircrafts Segment to Dominate MEA Aircraft Floor Panel Market during 2019-2027
MEA Aircraft Floor Panel Market is expected to reach US$ 47.63 million by 2027 from US$ 33.96 million in 2019. The market is estimated to grow at a CAGR of 5.4% from 2020 to 2027.
The report provides trends prevailing in the MEA aircraft floor panel market along with the drivers and restraints pertaining to the market growth. Mounting emphasis on use of lightweight materials and increasing demand for air freighter fleet are the major factor driving the growth of the MEA aircraft floor panel market. However, Boeing’s disappointment from B737 max and cancellation of A380 program hinder the growth of MEA
Press release content from Business Wire. The AP news staff was not involved in its creation.
South America Braking Resistors Market 2021-2027: Oil & Gas Segment is Expected to be Fastest Growing Sector - ResearchAndMarkets.com
March 8, 2021 GMT
DUBLIN (BUSINESS WIRE) Mar 8, 2021
Oil & Gas Segment is Expected to be Fastest Growing During Forecast Period for SAM Region
“SAM Braking resistors Market is expected to reach US$ 370.4 million by 2027 from US$ 258.4 million in 2019. The market is estimated to grow at a CAGR of 5.0% from 2020 to 2027.
The report provides trends prevailing in the SAM braking resistors market along with the drivers and restraints pertaining to the market growth. Rising adoption of advanced grids is the major factor driving the growth of the SAM braking resistors market. However, high motor heating issues hinders the growth of SAM braking resistors market.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Magic Reports Fourth Quarter and Full Year 2020 Financial Results with Record-Breaking Annual .
Magic Software Enterprises Ltd.March 8, 2021 GMT
Or Yehuda, Israel, March 08, 2021 (GLOBE NEWSWIRE) Magic Software Enterprises Ltd. (NASDAQ and TASE: MGIC), a global provider of end-to-end integration and application development platform solutions and IT consulting services, announced today its financial results for the fourth quarter and full year ended December 31, 2020.
Financial Highlights for the Fourth Quarter Ended December 31, 2020
Revenues for the fourth quarter increased 15% to a record-breaking $104.6 million compared to $90.9 million in the same period last year.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento .
Sorrento Therapeutics, Inc.March 8, 2021 GMT Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm.
China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
SAN DIEGO, March 07, 2021 (GLOBE NEWSWIRE) China Oncology Focus Limited (COF), an affiliate of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cle